Skip to main content

Market Overview

Arena Pharma's Olorinab Fails To Top Placebo In IBS-Related Abdominal Pain


Arena Pharmaceuticals Inc (NASDAQ: ARNA) has announced topline data from Phase 2b CAPTIVATE trial evaluating olorinab for abdominal pain due to Irritable Bowel Syndrome (IBS).

  • Although olorinab was well tolerated, the results show that it did not meet the primary efficacy endpoint of a statistically significant improvement in the overall abdominal pain score from baseline to week 12.
  • Within the participants with a baseline abdominal pain score of more than 6.5 (median), the 50 mg treatment group showed a clinically meaningful and statistically significant reduction in pain score of 1.64 points compared to placebo and 3.93 points from baseline at week 12.
  • Olorinab was generally safe and well-tolerated in the study, notably with no worsening of bowel habits and no treatment interruptions.
  • The company expects to evaluate possible strategic options for olorinab.
  • Olorinab (APD371) is an oral, peripherally acting, highly selective, full agonist of the cannabinoid receptor 2, designed to provide pain relief while minimizing the risk of psychoactive adverse effects.
  • Price Action: ARNA shares closed 4.1% lower at $76.81.

Related Articles (ARNA)

View Comments and Join the Discussion!

Posted-In: Irritable Bowel Syndrome Phase 2B TrialBiotech News Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at